Shilpa Gupta, MD, on a 4-Year Update From EV-103: Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma

Posted: Sunday, June 4, 2023

Shilpa Gupta, MD, of Cleveland Clinic, discusses the 4-year follow-up data from EV-103 on the use of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab in the first-line treatment of cisplatin-ineligible, locally advanced or metastatic urothelial carcinoma. The updated trial findings showed the continued benefits of this combination immunotherapy in this patient population.